In this webinar, hear from The Protein Society and invited speakers from Schrödinger, UCB, and Nested Therapeutics as they discuss three real-life drug discovery case studies that were impacted by the use of physics-based molecular simulations.

Achieving kinome-wide selectivity in drug discovery campaigns through free energy calculations: a Wee1 case study
Dr. Jennifer Knight, Schrödinger

Driving drug discovery by physics-based simulations: Multifaceted impact beyond chemistry prioritization
Dr. Aysegul Ozen, Nested Therapeutics